Darley Oaks

Darley Oaks is a clinical-stage biotechnology company focused on developing next-generation therapies for food allergies, with a primary focus on peanut allergy. The company was founded by a team of industry veterans, including former leadership from Aimmune Therapeutics, the developers of the first FDA-approved peanut allergy treatment. Darley Oaks' lead candidate, DOT-201, is an oral small molecule designed to inhibit the high-affinity IgE receptor (FcεRI) signaling pathway, potentially offering a safer and more convenient alternative to traditional oral immunotherapy. By targeting the underlying biological drivers of allergic reactions, the company aims to provide significant protection against accidental allergen exposure while improving patient compliance and quality of life. Darley Oaks is currently advancing its pipeline through early-stage clinical trials to validate its approach in desensitizing patients with life-threatening allergies.